Brosman S A
J Urol. 1982 Jul;128(1):27-30. doi: 10.1016/s0022-5347(17)52736-6.
A randomized study was done on 49 patients with a history of recurrent superficial transitional cell carcinoma of the bladder to determine if the frequency of tumor recurrence could be lessened. The patients were treated with 6 weekly instillations of Tice strain bacillus Calmette-Guerin or thio-tepa, followed by instillations every 2 weeks for 3 months and every month until a recurrence developed or the patients had been treated for 2 years. Twelve additional patients who had previously failed on thio-tepa were placed on the bacillus Calmette-Guerin protocol. There have been no recurrences in the bacillus Calmette-Guerin group, while 9 patients (40 per cent) in the thio-tepa group suffered recurrences. All of the patients treated with bacillus Calmette-Guerin had symptoms of bladder irritability after each instillation. The same type of irritability occurred in 7 patients (25 per cent) in the thio-tepa group. Severe complications occurred in 11 patients treated with bacillus Calmette-Guerin (28 per cent), 4 of whom required hospitalization. Another 12 patients with visible transitional cell carcinoma were treated with weekly instillations of bacillus Calmette-Guerin. Of these patients 6 had total resolution after 18 weekly instillations and 2 had no detectable tumor after 24 weeks of therapy. Two patients were free of tumor after 6 instillations. Of 7 patients with carcinoma in situ treated with weekly instillations of bacillus Calmette-Guerin 5 had complete resolution of the cellular atypia after 18 weeks of therapy. These studies confirm and extend those of others by demonstrating that bladder instillations of bacillus Calmette-Guerin are effective in reducing the recurrence rate in patients with superficial bladder tumor and can eliminate existing tumor in some patients. Symptoms of bladder irritability occur to a varying extent in every patient, and severe systemic toxicity occurred in 28 per cent of the patients.
对49例有膀胱浅表性移行细胞癌复发史的患者进行了一项随机研究,以确定肿瘤复发频率是否能够降低。患者接受6次每周一次的卡介苗Tice株或噻替派灌注治疗,随后每2周灌注一次,持续3个月,之后每月灌注一次,直至复发或患者接受治疗满2年。另外12例先前噻替派治疗失败的患者采用卡介苗方案治疗。卡介苗组无复发,而噻替派组有9例患者(40%)复发。所有接受卡介苗治疗的患者每次灌注后均出现膀胱刺激症状。噻替派组有7例患者(25%)出现同样类型的刺激症状。接受卡介苗治疗的11例患者(28%)出现严重并发症,其中4例需要住院治疗。另外12例有可见移行细胞癌的患者接受每周一次的卡介苗灌注治疗。这些患者中,6例在18次每周灌注后完全缓解,2例在治疗24周后未检测到肿瘤。2例患者在6次灌注后肿瘤消失。7例原位癌患者接受每周一次的卡介苗灌注治疗,其中5例在治疗18周后细胞异型性完全消失。这些研究通过证明膀胱灌注卡介苗可有效降低浅表性膀胱肿瘤患者的复发率,并能使部分患者消除现有肿瘤,证实并扩展了其他研究结果。每位患者均不同程度地出现膀胱刺激症状,28%的患者出现严重全身毒性反应。